4//SEC Filing
Nazzi Gianfranco 4
Accession 0001209191-20-016460
CIK 0000818686other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 8:11 AM ET
Size
10.0 KB
Accession
0001209191-20-016460
Insider Transaction Report
Form 4
Nazzi Gianfranco
EVP, Growth Markets Commercial
Transactions
- Exercise/Conversion
Ordinary Shares
2020-03-03+1,399→ 19,863.357 total - Sale
Ordinary Shares
2020-03-03$11.77/sh−548$6,448→ 19,315.357 total - Exercise/Conversion
Restricted Share Units
2020-03-03−1,399→ 1,400 total→ Ordinary Shares (1,399 underlying)
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.7300 to $11.8100, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001725018
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 8:11 AM ET
- Size
- 10.0 KB